Indolyl or indolinyl hydroxamate compounds

1. A compound of formula (I):

wherein

is a single bond or a double bond;

n is 0, 1, or 2;

R 1 is SO 2 R a , in which R a is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;

R 2 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, halo, cyano, nitro, OR b , SR b , S(O)R b , NHC(O)—CH═CH—C(O)R b , NHC(O)—CH═CH—C(O)NR c R d , SO 2 NR c R d , OC(O)R b , C(O)NR c R d , NR c R d , NHC(O)R b , NHC(O)NR c R d , or NHC(S)R c , in which each of R b , R c , and R d , independently, is H, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;

each of R 3 , R 4 , R 5 , and R 6 , independently is, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, halo, cyano, nitro, OR b , SR b , S(O)R b , CH═CH—C(O)NR c R d , NHC(O)—CH═CH—C(O)R b , NHC(O)—CH═CH—C(O)NR c R d , SO 2 NR c R d , OC(O)R b , C(O)NR c R d , NR c R d , NHC(O)R b , NHC(O)NR c R d , or NHC(S)R c , in which each of R b , R c , and R d , independently, is H, hydroxy, alkoxy, aryloxy, heteroaryloxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl; and

when R 1 is SO 2 R a , R 2 is NHC(O)—CH═CH—C(O)R b or NHC(O)—CH═CH—C(O)NR c R d ; at least one of R 3 , R 5 , and R 6 is CH═CH—C(O)NR c R d , NHC(O)—CH═CH—C(O)R b , or NHC(O)—CH═CH—C(O)NR c R d ; or R 4 is C(O)NR c R d , CH═CH—C(O)NR c R d , NHC(O)—CH═CH—C(O)R b , or NHC(O)—CH═CH—C(O)NR c R d .

2. The compound of claim 1 , wherein R 4 is CH═CH—C(O)NR c R d , NHC(O)—CH═CH—C(O)R b , or NHC(O)—CH═CH—C(O)NR c R d .

3. The compound of claim 1 , wherein R 4 is C(O)NHOH, CH═CH—C(O)NHOH, NHC(O)—CH═CH—C(O)OH, or NHC(O)—CH═CH—C(O)NHOH.

4. The compound of claim 3 , wherein R 4 is CH═CH—C(O)NHOH.

5. The compound of claim 4 , wherein R 1 is SO 2 R a and R a is aryl or heteroaryl.

6. The compound of claim 5 , wherein R a is phenyl optionally substituted with halo, hydroxyl, alkoxyl, amino, cyano, or nitro.

7. The compound of claim 1 , wherein R 2 is NHC(O)—CH═CH—C(O)R b or NHC(O)—CH═CH—C(O)NR c R d ; or at least one of R 3 , R 5 , and R 6 is CH═CH—C(O)NR c R d , NHC(O)—CH═CH—C(O)R b , or NHC(O)—CH═CH—C(O)NR c R d .

8. The compound of claim 7 , wherein R 1 is SO 2 R a and R a is aryl or heteroaryl.

9. The compound of claim 8 , wherein R a is phenyl optionally substituted with halo, hydroxyl, alkoxyl, amino, cyano, or nitro.

10. The compound of claim 1 , wherein R 1 is SO 2 R a and R a is aryl or heteroaryl.

11. The compound of claim 10 , wherein R a is phenyl optionally substituted with halo, hydroxyl, alkoxyl, amino, cyano, or nitro.

12. The compound of claim 1 , wherein the compound is one of the following compounds:

13. The compound of claim 12 , wherein the compound is 3-(1-benzenesulfonyl-1H-indol-5-yl)-N-hydroxy-acrylamide or 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide.

14. A method for treating leukemia, non-small cell lung cancer, breast cancer, or hepatocellular cancer, comprising administering to a subject in need thereof an effective amount of a compound of claim 1 .

15. A method for treating leukemia, non-small cell lung cancer, breast cancer, or hepatocellular cancer, comprising administering to a subject in need thereof an effective amount of a compound of claim 2 .

16. A method for treating leukemia, non-small cell lung cancer, breast cancer, or hepatocellular cancer, comprising administering to a subject in need thereof an effective amount of a compound of claim 10 .

17. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition, comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition, comprising a compound of claim 10 and a pharmaceutically acceptable carrier.